Why Pfizer Stock Still Looks Deeply Undervalued In 2026
BridgeBio Pharma Inc BBIO
$66.00
▲ +1.04%
(+$0.68)
Open
$64.56
Prev Close
$65.32
Day Range
$64.52 – $67.00
52W Range
$31.77 – $84.94
Market Cap
$12.79B
Beta
0.99
EPS (TTM)
$-3.75
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-06-27 |
| Shares Out. | 193,860,000 |
| Website | bridgebio.com/ ↗ |
| Phone | 13026587581 |
BridgeBio Pharma Inc is a publicly traded company under the ticker symbol BBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
30 analysts (2026-05-01)
📰 Latest News for BBIO
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 - Slideshow
Transcript : BridgeBio Pharma, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 02
BridgeBio submits NDA to FDA for encaleret for individuals living with ADH1
BridgeBio Submits FDA New Drug Application For Encaleret For Individuals Living With ADH1
BridgeBio Pharma : BBIO - Encaleret - ADH1 - Primary Results from Phase 3 CALIBRATE Trial
BridgeBio Pharma : BBIO-Acoramidis-ESC-HF2026 KCCQ-improvement